BioXcel Therapeutics, Inc. (BTAI) came out with a quarterly loss of $3.57 per share versus the Zacks Consensus Estimate of a loss of $4.36. This compares to loss of $12.16 per share a year ago. These ...

NEW HAVEN, Conn., March 27, 2025 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in ...

Apollo Health, a leading provider of clinically proven innovative health solutions for cognition, has partnered with Trifecta Nutrition, the nation's largest science-backed meal delivery service ...

Nurix Therapeutics (NRIX) announced that the U.S. Food and Drug Administration, FDA, has granted Orphan Drug Designation, ODD, to bexobrutideg, ...

Bexobrutideg is an orally bioavailable, brain penetrant degrader of BTK which is being evaluated ... There are no therapies approved to treat WM patients after a BTKi. About Nurix Therapeutics, Inc.

AI-powered stock picks with a proven track record to beat the S&P 500.

HEM Pharma announced on the 12th that it has signed a memorandum of understanding (MOU) with Xcell Therapeutics for research and commercialization collaboration on microbiome-based bio-materials.

Viking Therapeutics' stock declined by 37% following a downgrade to "hold" in December, anticipating competitive pressures from Novo Nordisk's CagriSema Phase 3 results. The company's GIP/GLP-1 ...

Born in Leeds, Joe finished his Spanish degree in 2018 before becoming an English teacher to football (soccer) players and managers, as well as collaborating with various football media outlets in ...

MONTREAL--(BUSINESS WIRE)--Ventus Therapeutics, a clinical-stage biopharmaceutical ... VENT-02 is a novel, oral, brain-penetrant inhibitor of NLRP3, a key driver of inflammation and component ...